The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy

The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy

The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylit...

Full description

Bibliographic Details
Main Authors: Elsa Vieira-Sousa, Helena Canhão, Pedro Alves, Ana Maria Rodrigues, Filipa Teixeira, José Tavares-Costa, Alexandra Bernardo, Sofia Pimenta, Fernando Pimentel-Santos, João L Gomes, Renata Aguiar, Taciana Videira, Patrícia Pinto, Cristina Catita, Helena Santos, Joana Borges, Graça Sequeira, Célia Ribeiro, Lídia Teixeira, Pedro Ávila-Ribeiro, Fernando M Martins, Ruy M Ribeiro, João Eurico Fonseca
Format: Article
Language:English
Published: Sociedade Portuguesa de Reumatologia 2018-04-01
Series:Acta Reumatológica Portuguesa
Subjects:
clinical trial
treatment algorithm
psoriatic arthritis
dactylitis
Online Access:http://www.actareumatologica.com/files/article/1214_the_go_dact_protocol_a_multicentre_randomized_double_blind_parallel_group_study_to_compare_the_efficacy_of_golimumab_in_combination_with_methotrexate_mtx_versus_mtx_monotherapy_file.pdf

Similar Items

Similar Items